Drug Trial Radar · NCT03822351
Durvalumab Alone or in Combination With Novel Agents in Subjects With NSCLC
Last checked: Nov 19, 2026Latest source record: Oct 8, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
189
Actual
Start
Dec 19, 2018
Primary completion
Jul 18, 2023
Study completion Jul 18, 2023
Sponsor
- Lead sponsor
- MedImmune LLCAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jan 30, 2019
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 99 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the clinical activity of durvalumab alone vs durvalumab in combination with novel agents. The overall study goal is early identification of novel durvalumab combinations that are more active than durvalumab alone in the treatment of patients with unresectable, Stage III NSCLC who have not progressed after cCRT.
Conditions
- Stage III Non-small Cell Lung Cancer
- Unresectable
Interventions
Durvalumab + OleclumabDrug
Durvalumab + Oleclumab
DurvalumabDrug
Durvalumab
Durvalumab + MonalizumabDrug
Durvalumab + Monalizumab
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response (OR) Rate as a Measure of Antitumor Activity of Durvalumab Alone vs Durvalumab in Combination With Novel AgentsTime frame: ORR at 16 weeks after randomization is the timing for radiologic assessment of the primary endpoint
Locations
73 sites in 9 countries. Site status is shown where the registry gives one.
Research Site
Anaheim, California
Research Site
Duarte, California
Research Site
Sacramento, California
Research Site
New Haven, Connecticut
Research Site
West Haven, Connecticut
Research Site
Washington D.C., District of Columbia
Research Site
Orlando, Florida
Research Site
Winter Haven, Florida
Research Site
Wichita, Kansas
Research Site
Lexington, Kentucky
Research Site
Louisville, Kentucky
Research Site
Baton Rouge, Louisiana
Research Site
Covington, Louisiana
Research Site
Rosedale, Maryland
Research Site
Lincoln, Nebraska
Research Site
New York, New York
Research Site
New York, New York
Research Site
Portland, Oregon
Research Site
Gettysburg, Pennsylvania
Research Site
Lancaster, Pennsylvania
Research Site
Philadelphia, Pennsylvania
Research Site
Sioux Falls, South Dakota
Research Site
Germantown, Tennessee
Research Site
Memphis, Tennessee
Research Site
Tyler, Texas
Research Site
Salt Lake City, Utah
Research Site
Richmond, Virginia
Research Site
Tacoma, Washington
Research Site
Edmonton, Alberta, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Bordeaux, France
Research Site
Brest, France
Research Site
Bron, France
Research Site
Créteil, France
Research Site
La Rochelle, France
Research Site
Lille, France
Research Site
Limoges, France
Research Site
Lyon, France
Research Site
Marseille, France
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.